Updated:
Forward Asset Management
鍾威亷’s Forward Asset Management runs a NT$892M biotech venture LP from Taipei, pairing Taiwan CDMO resources with drug-developer investments.
Forward Asset Management
Forward Asset Management is a private equity firm based in Taipei, Taiwan. It focuses on venture capital investments and manages approximately $27.47 million in assets, with $6.87 million in dry powder.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
Taiwan
City
Taipei
Corporate office
4F, No. 60, Xingzhong Road, Neihu District, Taipei City 114064
Principals
鍾威亷
董事長暨總經理 (Chairman & General Manager)
林晉源
策略長暨合夥人 (Chief Strategy Officer & Partner)
黃建達
合夥人 (Partner)
鍾昌杰
合夥人 (Partner)
Sector focus
Frequently asked questions
Who makes investment decisions at Forward Asset Management?
The four named partners — 鍾威亷 (Chairman and General Manager), 林晉源 (Chief Strategy Officer), 黃建達, and 鍾昌杰 — form the disclosed decision-making team. No distinction between an investment committee and a management committee is publicly available, and the firm has not published individual deployment limits or voting structures.
What is the structure and focus of Forward’s fund?
The firm manages a single disclosed vehicle, the 富耀生醫創投有限合夥 (Fuyue BioMed Venture Capital LP). It concentrates on specialty drug developers, companion-animal health companies, and biotech service providers that have already validated their technology. Forward targets companies ready for clinical acceleration, not seed-stage science projects.
How does Forward Asset Management support its portfolio beyond writing a check?
Forward explicitly ties its portfolio to Taiwan’s contract development and manufacturing network. The firm states it uses relationships with international CDMO and pharmaceutical manufacturing leaders in Taiwan to help companies speed up product development and enter new commercial markets — a manufacturing-intimacy layer most biotech VCs do not offer as a core service.
In which geographies does Forward invest?
The disclosed portfolio spans Taiwan and the United States. GeneFab, one of several US holdings, operates as a cell-and-gene-therapy CRDMO in the American market, while 寶泰生醫 targets the Asia-Pacific companion-animal health sector.
Which sectors does Forward explicitly avoid?
Forward has not published a negative list, but its entire disclosed book is confined to biotech — human therapeutics, drug-delivery devices, animal health, and biotech contract services. No investments appear in software, fintech, AI outside drug discovery, or consumer health.
Does Forward Asset Management take board seats, and is ownership publicly disclosed?
The firm does not publicly detail its governance model or whether partners occupy board seats. Ownership of the general partner entity, 安瑞管理顧問, is not disclosed, and no regulatory filings have made that structure public.
How does Forward measure success for its biotech investments?
Forward marks exits through public listings on Taiwan’s stock exchanges. The firm highlighted two milestones: 心誠鎂行動醫電 listed on the Taiwan Stock Exchange in February 2026, and 寶泰生醫 entered the Emerging Stock market in August 2025, signaling a path-to-liquidity strategy anchored in the local capital markets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: